Hemp-Derived THC Beverages Face Federal Regulatory Crossroads

Regulatory Agencies Signal Enforcement Intent

Federal agencies including the FDA and DEA have begun coordinating on potential rulemaking that would restrict or ban intoxicating hemp-derived cannabinoids in consumer products. The coordination follows three years of explosive growth in hemp-derived delta-8 THC, delta-9 THC, and THCA beverages sold outside state-licensed cannabis programs.

The Farm Bill legalized hemp containing less than 0.3% delta-9 THC by dry weight. Manufacturers exploited that threshold. They concentrated delta-9 THC in liquid products or converted CBD into intoxicating isomers like delta-8 THC. The result: beverages with 5-10 mg of THC per can, sold with no age verification in states where recreational cannabis remains illegal.

Market Scale and Distribution Footprint

Hemp-derived THC beverages generated an estimated $2 billion in retail sales in 2025, distributed through more than 50,000 convenience stores, liquor retailers, and grocery chains. Brands including Cann, Cycling Frog, and Day One built national distribution by sidestepping state cannabis licensing requirements.

Growth accelerated after Molson Coors, Constellation Brands, and Pabst Brewing entered the space through partnerships or acquisitions. Mainstream alcohol distributors now carry hemp THC products alongside beer and seltzers, treating them as just another SKU on the beverage aisle.

State-Level Enforcement Patchwork

At least 18 states have moved to ban or regulate intoxicating hemp products since 2023, creating a fragmented compliance landscape. Colorado, Oregon, and Minnesota enacted laws requiring hemp beverages to be sold only through licensed cannabis retailers. North Carolina and Montana imposed outright bans on delta-8 THC and other synthetic cannabinoids.

California's Department of Cannabis Control issued cease-and-desist letters to retailers selling non-licensed hemp THC products in June 2026. New York's Office of Cannabis Management followed with similar enforcement in August. Both states argued that intoxicating hemp products violate existing cannabis laws regardless of source material.

FDA's Intoxicating Hemp Policy Review

The FDA announced in July 2026 that it's conducting a comprehensive review of intoxicating hemp-derived cannabinoids, with a decision expected by the end of the calendar year. Since 2019, the agency has maintained that adding CBD or other cannabinoids to food and beverages violates the Federal Food, Drug, and Cosmetic Act, but enforcement has been inconsistent.

Industry attorneys note that the FDA has issued warning letters to CBD companies but hasn't yet taken action against major THC beverage brands. Some manufacturers interpret the agency's silence as tacit approval, though FDA officials have repeatedly stated that lack of enforcement doesn't imply legality.

DEA Scheduling Considerations

The DEA is evaluating whether synthetically derived or isomerized cannabinoids like delta-8 THC should be classified as controlled substances distinct from naturally occurring delta-9 THC. A 2023 interim final rule clarified that "synthetically derived tetrahydrocannabinols remain Schedule I controlled substances," but the agency hasn't defined the boundary between natural extraction and synthetic conversion.

If the DEA issues a final rule classifying delta-8 and similar compounds as Schedule I drugs, manufacturers would be required to destroy inventory and cease production immediately. Licensed cannabis operators in adult-use states have lobbied for this outcome, arguing that hemp-derived intoxicants undercut regulated markets.

Industry Response and Litigation Risk

Trade groups including the U.S. Hemp Roundtable and the Hemp Beverage Alliance have urged Congress to establish clear federal standards rather than leaving the category in legal limbo. Both organizations argue that an outright ban would eliminate thousands of jobs and billions in economic activity without addressing consumer demand for lower-dose THC products.

The hemp beverage industry has called for a regulated framework that includes potency limits, lab testing, and age-restricted sales—mirroring alcohol regulations rather than cannabis licensing.

Several manufacturers have retained litigation counsel in anticipation of federal enforcement. Legal challenges would likely center on whether the Farm Bill's hemp definition preempts agency rulemaking and whether the DEA's authority extends to cannabinoids derived from legal hemp.

What Operators and Investors Are Watching

The next 90 days will determine whether the hemp THC beverage category survives in its current form. Key decision points include the FDA's year-end policy statement, potential DEA scheduling action, and whether Congress addresses the issue in the 2027 Farm Bill reauthorization.

Licensed cannabis operators are monitoring closely. If federal agencies shut down the hemp beverage market, demand could shift to state-licensed dispensaries, but only in the 24 states with legal adult-use programs. In prohibition states, eliminating hemp THC products would leave consumers with no legal access to cannabis beverages whatsoever.

For more background on this evolving regulatory landscape, see the CannIntel topic hub on hemp-derived THC beverages.